# Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

> **NCT01186406** · PHASE2 · TERMINATED · sponsor: **Duke University** · enrollment: 41 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Gliosarcoma

## Interventions

- **DRUG:** Gliadel
- **RADIATION:** Radiation Therapy
- **DRUG:** Avastin
- **DRUG:** Temodar

## Key facts

- **NCT ID:** NCT01186406
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2014-06-16
- **Final completion:** 2014-06-16
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Study ended early due to toxicity
- **Last updated:** 2019-02-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01186406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01186406, "Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01186406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*